JN
JNJ.US Johnson & Johnson
- Market cap
- USD 688B
- P/E
- 43.4x
- P/B
- 8.44x
- ROE
- 18.0%
- Dividend yield
- 1.80%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is JNJ.US undervalued?
Graham numberThe Graham number of Johnson & Johnson cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Johnson & Johnson fundamental analysis
No fundamental analysis for Johnson & Johnson yet.
Johnson & Johnson stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers,…
Full company profileJohnson & Johnson financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Johnson & Johnson annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 71.9B | 76.5B | 81.6B | 82.1B | 82.6B | 78.7B | 80.0B | 85.2B | 88.8B | 94.2B | 99.7B |
| Gross Profit | 50.1B | 51.0B | 54.5B | 54.5B | 54.2B | 55.3B | 55.4B | 58.4B | 61.4B | 63.9B | 67.4B |
| Operating Income | 20.9B | 18.9B | 21.2B | 21.0B | 19.7B | 20.9B | 21.0B | 21.9B | 22.1B | 25.6B | 25.9B |
| EBITDA | 24.3B | 24.2B | 25.9B | 24.7B | 23.9B | 26.8B | 26.6B | 29.3B | 24.8B | 41.1B | 26.2B |
| Net Income | 16.5B | 1.30B | 15.3B | 15.1B | 14.7B | 20.9B | 17.9B | 35.2B | 14.1B | 26.8B | 14.6B |
| EPS | 5.93 | 0.47 | 5.61 | 5.63 | 5.51 | 7.81 | 6.73 | 14 | 5.79 | 11 | 5.98 |
| Balance Sheet | |||||||||||
| Total Assets | 141B | 157B | 153B | 158B | 175B | 182B | 187B | 168B | 180B | 199B | 197B |
| Total Liabilities | 70.8B | 97.1B | 93.2B | 98.3B | 112B | 108B | 111B | 98.8B | 109B | 118B | 116B |
| Shareholders' Equity | 70.4B | 60.2B | 59.8B | 59.5B | 63.3B | 74.0B | 76.8B | 68.8B | 71.5B | 81.5B | 81.5B |
| Cash & Short-term Investments | 41.9B | 18.3B | 19.7B | 19.3B | 25.2B | 31.6B | 22.3B | 22.9B | 24.5B | 20.1B | 17.2B |
| Total Debt | 27.1B | 34.6B | 30.5B | 27.7B | 35.3B | 33.8B | 39.6B | 29.3B | 36.6B | 47.9B | 44.7B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 18.8B | 21.1B | 22.2B | 23.4B | 23.5B | 23.4B | 21.2B | 22.8B | 24.3B | 24.5B | 25.1B |
| Capital Expenditure | 3.23B | 3.28B | 3.67B | 3.50B | 3.35B | 3.65B | 4.01B | 4.54B | 4.42B | 4.83B | 4.98B |
| Free Cash Flow | 15.5B | 17.8B | 18.5B | 19.9B | 20.2B | 19.8B | 17.2B | 18.2B | 19.8B | 19.7B | 20.2B |
| Ratios | |||||||||||
| ROE | 23.5% | 2.2% | 25.6% | 25.4% | 23.3% | 28.2% | 23.4% | 51.1% | 19.7% | 32.9% | 18.0% |
| ROA | 11.7% | 0.8% | 10.0% | 9.6% | 8.4% | 11.5% | 9.6% | 21.0% | 7.8% | 13.5% | 7.4% |
| Net Profit Margin | 23.0% | 1.7% | 18.8% | 18.4% | 17.8% | 26.5% | 22.4% | 41.3% | 15.8% | 28.5% | 14.7% |
| Debt to Equity | 0.39x | 0.57x | 0.51x | 0.47x | 0.56x | 0.46x | 0.52x | 0.43x | 0.51x | 0.59x | 0.55x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Johnson & Johnson dividends
- Dividend yield
- 1.80%
- Forward dividend
- 5.36 USD
- Payout ratio
- 46.2%
- Ex-dividend date
- Nov 24, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 12.4B | 5.10 | 46.2% |
| 2024 | USD 11.8B | 4.87 | 84.1% |
| 2023 | USD 11.8B | 4.60 | 33.5% |
| 2022 | USD 11.7B | 4.39 | 65.1% |
| 2021 | USD 11.0B | 4.13 | 52.8% |
| 2020 | USD 10.5B | 3.92 | 71.2% |
| 2019 | USD 9.92B | 3.69 | 65.6% |
| 2018 | USD 9.49B | 3.48 | 62.1% |
| 2017 | USD 8.94B | 3.26 | 687.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Jun 13, 2001.
Who owns Johnson & Johnson
- Insiders 0.22%
- Institutions 77.07%
- Public & others 22.71%
- Shares outstanding 2.41B
- Free float 2.40B
Top funds holding JNJ.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 76.5M | 3.18% | -0.01% | Sep 2026 |
| Vanguard 500 Index Investor | 63.3M | 2.63% | -1.03% | Sep 2026 |
| iShares Core S&P 500 ETF | 32.1M | 1.33% | +0.17% | Oct 2026 |
| Fidelity 500 Index | 31.3M | 1.30% | +0.23% | Sep 2026 |
| State Street® SPDR® S&P 500® ETF | 29.4M | 1.22% | -0.25% | Oct 2026 |
| Vanguard MStar Value Index Investor | 23.0M | 0.95% | -0.23% | Sep 2026 |
| State Street®HlthCrSelSectSPDR®ETF | 17.6M | 0.73% | +0.88% | Oct 2026 |
| Vanguard Dividend Appreciation ETF | 13.6M | 0.57% | +0.06% | Sep 2026 |
| Vanguard Institutional Index I | 12.7M | 0.53% | -0.94% | Sep 2026 |
| Vanguard High Dividend Yield ETF | 9.80M | 0.41% | +0.27% | Sep 2026 |
| American Funds Washington Mutual A | 9.73M | 0.40% | +110.29% | Sep 2026 |
| Vanguard Health Care ETF | 7.26M | 0.30% | +0.13% | Sep 2026 |
| Vanguard Health Care Inv | 7.19M | 0.30% | +4.42% | Sep 2026 |
| JPMorgan Large Cap Growth I | 7.17M | 0.30% | -0.91% | Sep 2026 |
| Columbia Dividend Income Inst | 7.02M | 0.29% | -0.58% | Sep 2026 |
| State Street® SPDR® Port S&P 500® ETF | 6.70M | 0.28% | -0.07% | Oct 2026 |
| iShares Core S&P 500 ETF USD Acc | 5.79M | 0.24% | 0.00% | Oct 2026 |
| Vanguard Equity-Income Inv | 5.50M | 0.23% | -6.46% | Sep 2026 |
| Schwab® S&P 500 Index | 5.41M | 0.22% | +0.22% | Sep 2026 |
| iShares Russell 1000 Value ETF | 5.30M | 0.22% | +0.02% | Oct 2026 |
Top institutions holding JNJ.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 212M | 8.81% | -0.60% | Jun 2026 |
| Vanguard Capital Management, LLC | 157M | 6.53% | +0.40% | Jun 2026 |
| State Street Corp | 134M | 5.56% | +0.22% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 64.4M | 2.67% | +1.35% | Jun 2026 |
| Geode Capital Management, LLC | 59.1M | 2.45% | -0.13% | Jun 2026 |
| JPMorgan Chase & Co | 58.3M | 2.42% | -7.60% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 44.8M | 1.86% | +0.19% | Jun 2026 |
| NORGES BANK | 31.8M | 1.32% | -4.89% | Jun 2026 |
| State Farm Mutual Automobile Ins Co | 31.6M | 1.31% | 0.00% | Sep 2026 |
| Northern Trust Corp | 28.8M | 1.20% | -1.80% | Jun 2026 |
| Bank of America Corp | 23.4M | 0.97% | -8.15% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 23.0M | 0.96% | +39.45% | Jun 2026 |
| FMR Inc | 22.6M | 0.94% | -8.79% | Jun 2026 |
| Wellington Management Company LLP | 22.6M | 0.94% | +12.52% | Jun 2026 |
| Bank of New York Mellon Corp | 21.7M | 0.90% | -0.64% | Jun 2026 |
| The Goldman Sachs Group Inc | 19.7M | 0.82% | +9.22% | Jun 2026 |
| Legal & General Group PLC | 19.3M | 0.80% | -0.32% | Jun 2026 |
| Charles Schwab Investment Management Inc | 19.1M | 0.79% | -0.27% | Jun 2026 |
| UBS Asset Mgmt Americas Inc | 18.4M | 0.77% | -6.17% | Jun 2026 |
| Wells Fargo & Co | 17.4M | 0.72% | +2.65% | Jun 2026 |
Johnson & Johnson company profile
- Company name
- Johnson & Johnson
- Ticker
- JNJ.US
- Exchange
- USA Stocks
- Listed since
- Sep 24, 1944
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 138,200
- Fiscal year end
- December
- Address
- One Johnson & Johnson Plaza, New Brunswick, NJ, United States, 08933
- Phone
- 732 524 0400
- Website
- jnj.com
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Johnson & Johnson management
10- Mr. Joaquin DuatoCEO & Chairman · born 1963
- Mr. Joseph James Wolk CPAExecutive VP & CFO · born 1967
- Dr. John C. Reed M.D., Ph.D.Executive Vice President of Innovative Medicine and R&D · born 1958
- Mr. Timothy SchmidExecutive VP & Worldwide Chairman of MedTech · born 1970
- Mr. Robert J. Decker Jr.Controller & Chief Accounting Officer · born 1973
- Mr. James SwansonExecutive VP & Chief Information Officer · born 1966
- Mr. Ryan KoorsVice President of Investor Relations
- Mr. Dirk BrinckmanChief Compliance Officer
- Ms. Elizabeth Forminard J.D.Executive VP & Chief Legal Officer · born 1971
- Ms. Kristen Blair MulhollandExecutive VP & Chief Human Resources Officer · born 1967